Health Condition 1: D693- Immune thrombocytopenic purpura
Conditions
Interventions
Intervention1: Dexamethasone: Dexamethasone will be gievn at a dose of 24 mg/m2 (maximum 40 mg) divided into two doses for 1 cycle and if required 2 or 3 cycles if no response noted in 1 cycle or 2 cy
Sponsors
All India Institute of Medical Sciences, Patna
Eligibility
Inclusion criteria
Inclusion criteria: Patients of ITP visiting OPD/admitted in Paediatrics ward of AIIMS Patna who are between 1 to 18 years of age and have not received steroids in past 1 month and require treatment as per the protocol
Exclusion criteria
Exclusion criteria: 1. Patients with inherited platelet disorders (Bernard-Soulier syndrome, Glanzmann thrombasthenia, etc.) 2. Patients with known rheumatological diseases already on steroids or steroid sparing drugs (SLE, APLA, etc.) 3. Patients with known malignancy receiving chemotherapy and/or radiotherapy. 4. Patients of aplastic anemia 5. Patients of chronic or persistent ITP 6. Patients taking antiplatelet drugs. 7. Patients who received steroid(s) or IVIG or platelet transfusion(s) prior to presenting to AIIMS Patna.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement or resolution of thrombocytopeniaTimepoint: At baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7, 1 month and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| a. To assess the likelihood of progression to persistent ITP in children treated with dexamethasone as compared to that with of prednisolone.Timepoint: 6 months;b. Time spent under the danger zone of risk of bleeding i.e., platelet count less than 20,000/mm3 during treatment with either agentTimepoint: 6 months;To assess the need for platelet transfusion in both categoriesTimepoint: 6 months;To compare the steroid toxicity/adverse effects in both categoriesTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactUtkarsh Srivastava
All India Institute of Medical Sciences, Patna
Outcome results
None listed